| (EUR) | Jun 2026 | Y/Y change |
|---|---|---|
| Revenue | 0.00 | — |
| Operating expense | — | — |
| Net income | -5.45M | — |
| Net profit margin | — | — |
| Earnings per share | — | — |
| EBITDA | — | — |
| Effective tax rate | — | — |
Over the past year, 137.F returned -73.6% with dividends reinvested.
| Period | Total return |
|---|---|
| YTD | -70.1% |
| 1 year | -73.6% |
| 5 years | -82.7% |
| 10 years | -74.3% |
| All-time high | €11.97 (Sep 2018) |
Returns are total returns and include reinvested dividends. The all-time high is the highest monthly closing price on record.
See what €1,000 in 137.F would be worth today ›No. Aldeyra Therapeutics, Inc. has not paid a dividend in the past 12 months.
Aldeyra Therapeutics, Inc. is part of the Healthcare sector.
Aldeyra Therapeutics, Inc. has a market cap of 77.82M EUR, based on the latest quote.
Aldeyra Therapeutics, Inc. is expected to report earnings around Nov 4, 2026. That date is an estimate and has not been confirmed by the company.